Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

Core Insights - Entera Bio Ltd. is set to present data on three key programs in September 2025, focusing on oral peptide and protein replacement therapies for significant medical needs [1][4][7] Osteoporosis Program - EB613 is being developed as the first once-daily oral anabolic tablet for postmenopausal women with osteoporosis, showing rapid onset of action and increases in bone mineral density (BMD) in a Phase 2 study involving 161 participants [1][7] - A global Phase 3 registration study for EB613 is planned following alignment with the FDA, with BMD as the primary endpoint [7] Short Bowel Syndrome and Rare GI Disorders - The oral GLP-2 tablet program combines a long-acting GLP-2 agonist with Entera's proprietary N-Tab™ technology, providing an injection-free alternative for patients with short bowel syndrome and related gastrointestinal disorders [2][7] Upcoming Presentations - Entera's CEO will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, highlighting the company's advancements in oral peptide therapies [3][4] - Specific presentations include the effects of EB613 on trabecular and cortical bone and pre-clinical data for Next-Gen EB613 [5][6]